<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255382</url>
  </required_header>
  <id_info>
    <org_study_id>M16-178</org_study_id>
    <secondary_id>2016-003718-28</secondary_id>
    <nct_id>NCT03255382</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are NaYve to and Candidates for Systemic Therapy</brief_title>
  <official_title>A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL 23p19 Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of subcutaneous (SC)
      risankizumab and oral FUMADERM provided as study medication in subjects with moderate to
      severe plaque psoriasis who are naïve to and candidates for systemic therapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Anticipated">August 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 28, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Denotes greater than or equal to 90% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a PASI 75 response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Denotes greater than or equal to 75% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient Benefit Index (PBI)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The PBI is a patient-reported outcome instrument that assesses the benefit of psoriasis treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Surface Area (BSA) affected by psoriasis</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>BSA affected by psoriasis as assessed by the Investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with Static Physician Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Severity of Nail Psoriasis (NAPPA-CLIN)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The NAPPA-CLIN is used to assess the severity of nail matrix psoriasis (leukonychia, red spots, dots, nail plate crumbling) and psoriasis of the nail bed (oil drop, splinter haemorrhage, subungual hyperkeratosis, onycholysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a PASI 50 response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Denotes greater than or equal to 50% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a PASI 90 response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Denotes greater than or equal to 90% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with PSS of 0 (none)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The PSS is a four-item patient-reported outcome instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis. Scores range from 0 (none) to 4 (very severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Medical Outcomes Short Form Health Survey 36, version 2 (SF-36 V2): Physical Component Summary (PCS) Score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The SF-36 V2 Health is a 36-item general health self-administered questionnaire consisting of 8 scales measuring Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hospital Anxiety &amp; Depression Scale (HADS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The HADS is a self-assessment scale which detects the presence and severity of anxiety and depression in the general population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with a PASI 100 response</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Denotes greater than or equal to 100% improvement in PASI score. PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Palmoplantar Psoriasis Severity Index (PPASI)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The PPASI combines the percent of surface area of hands and feet that are affected and the severity of erythema, induration, and desquamation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Patient's Global Assessment (PtGA)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The PtGA is a patient-reported outcome instrument to assess the patient's assessment of disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with sPGA score of 0 (clear)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The sPGA is the physician's current assessment of the average thickness, erythema, and scaling of all psoriatic lesions. Scores range from 0 (clear) to 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PASI</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>PASI provides a quantitative assessment of psoriasis disease state based on the amount of body surface area that is affected and the degree of severity of erythema, induration, and scale, weighted by body part.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Psoriasis Symptom Scale (PSS)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The PSS is a four-item patient-reported outcome instrument that assesses the severity of psoriasis symptoms in patients with moderate to severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Psoriasis Scalp Severity Index (PSSI)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The PSSI is used by the physician to assess scalp psoriasis, including the erythema (redness), induration (hardness), desquamation (shedding of skin) and percent of scalp covered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with DLQI scores of 0 (not relevant/not at all) or 1 (a little)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status. Scores range from 0 (not relevant/not at all) to 3 (very much).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the European Quality of Life 5 Dimensions (EQ-5D-5L) .</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Medical Outcomes Short Form Health Survey 36, version 2 (SF-36 V2): Mental Component Summary (MCS) Score</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The SF-36 V2 Health is a 36-item general health self-administered questionnaire consisting of 8 scales measuring Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The DLQI is a self-administered, ten-question questionnaire used to assess the effect of different skin diseases on a subject's quality of life, overall health, and disability status.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Risankizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive risankizumab for16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fumaderm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants to received Fumaderm for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fumaderm</intervention_name>
    <description>tablet</description>
    <arm_group_label>Fumaderm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risankizumab</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>Risankizumab</arm_group_label>
    <other_name>ABBV-066 BI 655066</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of chronic plaque psoriasis for at least 6 months before the first
             administration of study drug. Duration since diagnosis may be reported by the patient

          -  Subject has stable moderate to severe plaque psoriasis with or without psoriatic
             arthritis at Baseline

          -  Must be naïve to and candidate for systemic therapy, as assessed by the investigator

          -  Subject has an inadequate response, intolerance or contraindication to topical
             psoriasis treatment

        Exclusion Criteria:

          -  Subjects with non-plaque forms of psoriasis

          -  Subject has previously received systemic therapy for psoriasis, whether biologic or
             non-biologic or photochemotherapy

          -  Active systemic infection during the last 2 weeks (exception: common cold) prior to
             screening.

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal or squamous cell carcinoma of
             the skin or in situ carcinoma of uterine cervix

          -  Subject has any condition or contraindication to Fumaderm that would preclude the
             patient's participation in the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Munster</name>
      <address>
        <city>Munster</city>
        <state>Niedersachsen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMS3 Company for Medical Study</name>
      <address>
        <city>Selters (Westerwald)</city>
        <state>Rheinland-Pfalz</state>
        <zip>56242</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum DermaKiel GmbH</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24148</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISA GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis</name>
      <address>
        <city>Blankenfeld-mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautzentrum Niesmann Othlingha</name>
      <address>
        <city>Bochum</city>
        <zip>44803</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hautklinik Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Klinik Eppendorf Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCIderm GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fur Dermatologie</name>
      <address>
        <city>Leipzig</city>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Johannes Gutenberg</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klin Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TU Uniklinik Munchen</name>
      <address>
        <city>Munich</city>
        <zip>80802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Tubingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoffmann, Witten, DE</name>
      <address>
        <city>Witten</city>
        <zip>58453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centroderm Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-0066</keyword>
  <keyword>BI 655066</keyword>
  <keyword>risankizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

